

Carlo Patrono

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5481163/carlo-patrono-publications-by-year.pdf>

Version: 2024-04-24

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

299
papers

37,470
citations

83
h-index

192
g-index

333
ext. papers

43,148
ext. citations

9.6
avg, IF

7.39
L-index

#	Paper	IF	Citations
299	Give genotype-guided dual antiplatelet therapy a second CHANCE.. <i>European Heart Journal</i> , 2022 ,	9.5	1
298	Age-independent benefits of blood pressure lowering: are they applicable to all patients?. <i>European Heart Journal</i> , 2022 , 43, 448-449	9.5	1
297	Therapeutic-dose heparin should integrate the standard of care of moderately ill patients with COVID-19 admitted to hospital.. <i>European Heart Journal</i> , 2022 , 43, 365-366	9.5	
296	Quadruple combination of quarter doses of blood pressure-lowering agents: a string QUARTET in the symphony of hypertension management?. <i>European Heart Journal</i> , 2021 , 42, 4885-4886	9.5	0
295	A fixed-dose combination treatment strategy to reduce premature cardiovascular disease deaths globally.. <i>European Heart Journal</i> , 2021 , 43, 16-17	9.5	
294	Another STEP towards tighter control of blood pressure in the elderly. <i>European Heart Journal</i> , 2021 , 42, 4715-4716	9.5	
293	Aldosterone receptor antagonism in patients with diabetes and chronic kidney disease: new promises and old problems. <i>European Heart Journal</i> , 2021 , 42, 14-15	9.5	1
292	COVID 19: in the eye of the cytokine storm. <i>European Heart Journal</i> , 2021 , 42, 150-151	9.5	9
291	The REDUCE-IT verdict on eicosapentaenoic acid and cardiovascular outcome challenged with STRENGTH. <i>European Heart Journal</i> , 2021 , 42, 370-371	9.5	3
290	The value of sotagliflozin in patients with diabetes and heart failure detracted by an unexpected ending. <i>European Heart Journal</i> , 2021 , 42, 1458-1459	9.5	2
289	Interleukin-1 blockade: a paradigm shift in the treatment of patients with recurrent pericarditis?. <i>European Heart Journal</i> , 2021 , 42, 1287-1288	9.5	
288	Aspirin at 120: Retiring, recombining, or repurposing?. <i>Research and Practice in Thrombosis and Haemostasis</i> , 2021 , 5, e12516	5.1	2
287	StatinWISE sheds new light on statin-related muscle symptoms. <i>European Heart Journal</i> , 2021 , 42, 1726-1727	9.5	0
286	Vulnerable non-culprit coronary plaques: are they worth treating?. <i>European Heart Journal</i> , 2021 , 42, 2233-2234	9.5	
285	The increased mortality of STEMI patients without risk factors supports the need for evidence-based pharmacotherapy irrespective of perceived low risk. <i>European Heart Journal</i> , 2021 , 42, 2329-2330	9.5	0
284	Are US cardiologists ADAPTABLE to considering low-dose aspirin for secondary prevention?. <i>European Heart Journal</i> , 2021 , 42, 2525-2526	9.5	0
283	A SPRINT towards tighter control of blood pressure in hypertension. <i>European Heart Journal</i> , 2021 , 42, 3042-3043	9.5	2

282	Challenging the Role of Aspirin for Long-Term Antiplatelet Therapy?. <i>European Heart Journal</i> , 2021 , 42, 2883-2884	9.5	0
281	The key role of blood pressure lowering in cardiovascular prevention irrespective of baseline blood pressure and risk profile. <i>European Heart Journal</i> , 2021 , 42, 2814-2815	9.5	3
280	COVID-19 vaccines: where we stand and challenges ahead. <i>Cell Death and Differentiation</i> , 2021 , 28, 626-637	9.5	333
279	The EMPEROR-Preserved study: end of the search for the "Phoenix" or beginning of a new season for trials in heart failure with preserved ejection fraction. <i>European Heart Journal</i> , 2021 , 42, 4621-4623	9.5	3
278	Physical activity and mortality reduction: is volume or intensity the key variable?. <i>European Heart Journal</i> , 2021 , 42, 730-731	9.5	0
277	Iron heart. <i>European Heart Journal</i> , 2021 , 42, 809-810	9.5	
276	Rivaroxaban, a novel option for patients with atrial fibrillation and a bioprosthetic mitral valve. <i>European Heart Journal</i> , 2021 , 42, 811-812	9.5	
275	The key contribution of platelet and vascular arachidonic acid metabolism to the pathophysiology of atherothrombosis. <i>Cardiovascular Research</i> , 2021 , 117, 2001-2015	9.9	9
274	Preventing a diabetes pandemic through lifestyle intervention. <i>European Heart Journal</i> , 2021 , 42, 226-227.5	9.5	
273	A one-size-fits-all polypill strategy for primary prevention in the era of precision medicine?. <i>European Heart Journal</i> , 2021 , 42, 561-562	9.5	1
272	Re-purposed antiviral drugs without a purpose in COVID-19: a valuable lesson for clinicians. <i>European Heart Journal</i> , 2021 , 42, 882-883	9.5	2
271	A randomized trial supports the recommendation to continue treatment with ACEi or ARBs during hospitalization for COVID-19. <i>European Heart Journal</i> , 2021 , 42, 1061-1062	9.5	1
270	PCSK9 inhibition: Not just LDL-Cholesterol knock down: A glimmer for cancer. <i>European Heart Journal</i> , 2021 , 42, 1130-1131	9.5	0
269	When less is more: dual antiplatelet therapy in elective percutaneous coronary intervention. <i>European Heart Journal</i> , 2021 , 42, 965-966	9.5	2
268	Occluding to prevent occlusion. <i>European Heart Journal</i> , 2021 , 42, 3224-3225	9.5	
267	Worsening of risk factor control in US diabetic patients: a call to action. <i>European Heart Journal</i> , 2021 , 42, 3120-3121	9.5	
266	A newly designed glucagon-like peptide-1 receptor agonist reduces cardiovascular and renal events in high-risk type 2 diabetes. <i>European Heart Journal</i> , 2021 , 42, 3902-3903	9.5	
265	Aspirin-free antiplatelet strategies: is the evidence supporting a paradigm shift?. <i>European Heart Journal</i> , 2021 , 42, 4011-4012	9.5	0

264	The cardiovascular benefits of statins outweigh adverse effects in primary prevention: results of a large systematic review and meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 4518-4519	9.5	0
263	Is tirzepatide in the surpass lane over GLP-1 receptor agonists for the treatment of diabetes?. <i>European Heart Journal</i> , 2021 , 42, 4211-4212	9.5	0
262	Does abbreviated dual antiplatelet therapy after PCI provide a clinically meaningful trade-off between bleeding and ischaemic events in patients at high risk for bleeding?. <i>European Heart Journal</i> , 2021 , 42, 4418-4419	9.5	
261	First in man: gene editing for the treatment of transthyretin amyloidosis. <i>European Heart Journal</i> , 2021 , 42, 3597-3598	9.5	
260	Abelacimab and factor XI inhibition: a novel mechanism for the prevention of venous thromboembolism. <i>European Heart Journal</i> , 2021 , 42, 4109-4110	9.5	1
259	Conflicting results on the efficacy of remdesivir in hospitalized Covid-19 patients: comment on the Adaptive Covid-19 Treatment Trial. <i>European Heart Journal</i> , 2020 , 41, 4387-4388	9.5	6
258	Do VERTIS-CV trial results question a class-effect of cardiovascular protection with sodium-glucose cotransporter 2 inhibitors?. <i>European Heart Journal</i> , 2020 , 41, 4232-4233	9.5	4
257	A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia. <i>Blood</i> , 2020 , 136, 171-182	2.2	33
256	In vivo thromboxane-dependent platelet activation is persistently enhanced in subjects with impaired glucose tolerance. <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3232	7.5	6
255	Aspirin in the primary prevention of cardiovascular disease in diabetes mellitus: A new perspective. <i>Diabetes Research and Clinical Practice</i> , 2020 , 160, 108008	7.4	10
254	Low-Dose Edoxaban for Stroke Prevention in Elderly Patients with Atrial Fibrillation: Comment on the Edoxaban Low-Dose for Elder Care Atrial Fibrillation Patients (ELDERCARE-AF) Trial. <i>European Heart Journal</i> , 2020 , 41, 3882-3883	9.5	2
253	EMPEROR-Reduced supports the use of SGLT2 inhibitors for the treatment of patients with heart failure and reduced ejection fraction: Comment on the EMPEROR-Reduced trial. <i>European Heart Journal</i> , 2020 , 41, 3881-3882	9.5	
252	The widely promoted antimalarial drug hydroxychloroquine confers no mortality benefit in hospitalized patients with COVID-19: comment on the 'Effect of Hydroxychloroquine in Hospitalized Patients with COVID-19'. <i>European Heart Journal</i> , 2020 , 41, 4389-4390	9.5	3
251	Out-of-Hospital Cardiac Arrest: Handle With Care-Comment on the Resuscitation Outcomes Consortium Cardiac Epidemiologic Registry. <i>European Heart Journal</i> , 2020 , 41, 4165-4166	9.5	
250	The second life of the ambiguous angiotensin-converting enzyme 2 as a predictive biomarker for cardiometabolic diseases and death. <i>European Heart Journal</i> , 2020 , 41, 4302-4303	9.5	1
249	Management of chronic kidney disease and its cardiovascular complications: has the dawn of a new era arrived? Comment on 'Dapagliflozin in Patients with Chronic Kidney Disease'. <i>European Heart Journal</i> , 2020 , 41, 4231-4232	9.5	1
248	Effect of Low-dose and Standard-dose Aspirin on PGE Biosynthesis Among Individuals with Colorectal Adenomas: A Randomized Clinical Trial. <i>Cancer Prevention Research</i> , 2020 , 13, 877-888	3.2	12
247	Aspirin Monotherapy vs. DAPT after TAVI: Is Less More? Comment on the POPular TAVI Trial. <i>European Heart Journal</i> , 2020 , 41, 4301-4302	9.5	2

246	New hope for targeted treatment of obstructive hypertrophic cardiomyopathy: comment on the EXPLORER-HCM trial. <i>European Heart Journal</i> , 2020 , 41, 4089-4090	9.5	1
245	Early rhythm control for early atrial fibrillation? Comment on the EAST-AFNET 4 Trial. <i>European Heart Journal</i> , 2020 , 41, 3987-3988	9.5	3
244	Decline in blood pressure control trends in the US: a real step back: Comment on National Health and Nutrition Examination Survey (NHANES) data. <i>European Heart Journal</i> , 2020 , 41, 3986-3987	9.5	
243	Weak hypothesis? Wrong pharmacologic tool? Inadequate experimental design? Comment on the ATPCI trial. <i>European Heart Journal</i> , 2020 , 41, 4166-4167	9.5	1
242	2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes. <i>European Heart Journal</i> , 2020 , 41, 407-477	9.5	1835
241	Aspirin as an adjuvant treatment for cancer: feasibility results from the Add-Aspirin randomised trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2019 , 4, 854-862	18.8	25
240	Role of aspirin in primary prevention of cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2019 , 16, 675-686	14.8	57
239	Fourth universal definition of myocardial infarction (2018).. <i>European Heart Journal</i> , 2019 , 40, 237-269	9.5	851
238	Platelet-Specific Deletion of Cyclooxygenase-1 Ameliorates Dextran Sulfate Sodium-Induced Colitis in Mice. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2019 , 370, 416-426	4.7	9
237	Arterial Grafts for Coronary Bypass: A Critical Review After the Publication of ART and RADIAL. <i>Circulation</i> , 2019 , 140, 1273-1284	16.7	28
236	Measurement of Thromboxane Biosynthesis in Health and Disease. <i>Frontiers in Pharmacology</i> , 2019 , 10, 1244	5.6	23
235	Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials. <i>The Lancet Gastroenterology and Hepatology</i> , 2018 , 3, 231-241	18.8	96
234	Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis. <i>European Heart Journal</i> , 2018 , 39, 1672-1686f	9.5	59
233	Aspirin, platelet inhibition and cancer prevention. <i>Platelets</i> , 2018 , 29, 779-785	3.6	37
232	The Aspirin Regimens in Essential Thrombocythemia (ARES) phase II randomized trial design: Implementation of the serum thromboxane B assay as an evaluation tool of different aspirin dosing regimens in the clinical setting. <i>Blood Cancer Journal</i> , 2018 , 8, 49	7	21
231	Gustav Born and life as "a series of ripples widening out from an original centre". <i>Platelets</i> , 2018 , 29, 761-762	3.6	
230	Off-Pump Coronary Artery Bypass Grafting: 30 Years of Debate. <i>Journal of the American Heart Association</i> , 2018 , 7, e009934	6	33
229	Low-Dose Aspirin Acetylates Cyclooxygenase-1 in Human Colorectal Mucosa: Implications for the Chemoprevention of Colorectal Cancer. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 52-61	6.1	22

228	In Silico Modeling of the Antiplatelet Pharmacodynamics of Low-dose Aspirin in Health and Disease. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 823-831	6.1	14
227	Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 238-245	6.1	31
226	On-pump Cardiac Surgery Enhances Platelet Renewal and Impairs Aspirin Pharmacodynamics: Effects of Improved Dosing Regimens. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 102, 849-858	6.1	18
225	Mechanisms, Consequences, and Prevention of Coronary Graft Failure. <i>Circulation</i> , 2017 , 136, 1749-1764	6.7	113
224	Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis. <i>Journal of the American College of Cardiology</i> , 2017 , 70, 1760-1776	15.1	100
223	Fighting residual cardiovascular risk in stable patients with atherosclerotic vascular disease: COMPASS in context. <i>Cardiovascular Research</i> , 2017 , 113, e61-e63	9.9	3
222	Questions and answers on antithrombotic therapy: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016 , 37, e1-e7	9.5	2
221	Questions and answers on coronary revascularization: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016 , 37, e8-e14	9.5	7
220	Questions and answers on diagnosis and risk assessment: a companion document of the 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016 , 37, e15-e21	9.5	7
219	2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). <i>European Heart Journal</i> , 2016 , 37, 267-315	9.5	3850
218	Homocysteine, methylenetetrahydrofolate reductase, folate status and atherothrombosis: A mechanistic and clinical perspective. <i>Vascular Pharmacology</i> , 2016 , 78, 1-9	5.9	47
217	Aspirin and Cancer. <i>Journal of the American College of Cardiology</i> , 2016 , 68, 967-76	15.1	153
216	Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs. <i>Current Cardiology Reports</i> , 2016 , 18, 25	4.2	31
215	CardioPulse: What's new in the 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. <i>European Heart Journal</i> , 2016 , 37, 206-7	9.5	5
214	In Vivo Platelet Activation and Aspirin Responsiveness in Type 1 Diabetes. <i>Diabetes</i> , 2016 , 65, 503-9	0.9	33
213	Aspirin prevents colorectal cancer metastasis in mice by splitting the crosstalk between platelets and tumor cells. <i>Oncotarget</i> , 2016 , 7, 32462-77	3.3	101
212	Background, fundamental concepts, and scientific evidence of the high-sensitivity cardiac troponin 0h/1h-algorithm for early rule-out or rule-in of acute myocardial infarction. <i>European Heart Journal</i> , 2016 , 37, 3318-3323	9.5	1
211	Patient-independent variables affecting the assessment of aspirin responsiveness by serum thromboxane measurement. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 891-896	7	11

210	Cardiovascular effects of cyclooxygenase-2 inhibitors: a mechanistic and clinical perspective. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 957-64	3.8	73
209	Should the 1h algorithm for rule in and rule out of acute myocardial infarction be used universally?. <i>European Heart Journal</i> , 2016 , 37, 3316-3323	9.5	21
208	1068 Direct Evidence for Long-Lasting Acetylation of Cyclooxygenase-1 Associated With Reduction of Colorectal Mucosa Prostaglandin E2 Levels and Ribosomal Protein S6 Phosphorylation by Low-Dose Aspirin in Subjects Undergoing Colorectal Cancer Screening. <i>Gastroenterology</i> , 2016 , 150, S211	13.3	2
207	Clinical Perspectives and Pearls from the 2015 ESC NSTEMI-ACS Guidelines. <i>Current Cardiology Reports</i> , 2016 , 18, 48	4.2	4
206	Antithrombotic therapy in the elderly: expert position paper of the European Society of Cardiology Working Group on Thrombosis. <i>European Heart Journal</i> , 2015 , 36, 3238-49	9.5	129
205	The Multifaceted Clinical Readouts of Platelet Inhibition by Low-Dose Aspirin. <i>Journal of the American College of Cardiology</i> , 2015 , 66, 74-85	15.1	75
204	Cyclooxygenase inhibitors: From pharmacology to clinical read-outs. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , 2015 , 1851, 422-32	5	126
203	Guía ESC 2015 sobre el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST: Grupo de Trabajo de la Sociedad Europea de Cardiología (ESC) para el tratamiento de los síndromes coronarios agudos en pacientes sin elevación persistente del segmento ST. <i>Revista Española De Cardiología</i> , 2015 , 68, 1125.e1-1125.e64	1.5	20
202	Nonsteroidal antiinflammatory drugs 2015 , 415-422		3
201	Guía de práctica clínica de la ESC sobre diabetes, prediabetes y enfermedad cardiovascular, en colaboración con la European Association for the Study of Diabetes. <i>Revista Española De Cardiología</i> , 2014 , 67, 136.e1-136.e56	1.5	8
200	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. <i>European Heart Journal</i> , 2014 , 35, 1824-1824	9.5	9
199	Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action. <i>Journal of Thrombosis and Haemostasis</i> , 2014 , 12, 1320-30	15.4	57
198	Coxibs and traditional NSAIDs for pain relief - Authors' reply. <i>Lancet, The</i> , 2014 , 383, 122	4.0	6
197	Nonsteroidal anti-inflammatory drugs and the heart. <i>Circulation</i> , 2014 , 129, 907-16	16.7	82
196	In vivo prostacyclin biosynthesis and effects of different aspirin regimens in patients with essential thrombocythaemia. <i>Thrombosis and Haemostasis</i> , 2014 , 112, 118-27	7	15
195	Knowledge about health effects of cigarette smoking and quitting among Italian university students: the importance of teaching nicotine dependence and treatment in the medical curriculum. <i>BioMed Research International</i> , 2014 , 2014, 321657	3	7
194	Role of clinical pharmacology in the development of antiplatelet drugs. <i>Clinical Therapeutics</i> , 2014 , 36, 2096-2111	3.5	6
193	ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD - summary. <i>Diabetes and Vascular Disease Research</i> , 2014 , 11, 133-73	3.3	137

192	Add-Aspirin trial: A phase III, double blind, placebo-controlled, randomized trial assessing the effects of aspirin on disease recurrence and survival after primary therapy in common nonmetastatic solid tumors.. <i>Journal of Clinical Oncology</i> , 2014 , 32, TPS1617-TPS1617	2.2	1
191	El ácido acetilsalicílico continúa siendo objeto de investigación y debate 115 años después de su síntesis. <i>Revista Española De Cardiología</i> , 2013 , 66, 251-254	1.5	2
190	Low-dose aspirin in primary prevention: cardioprotection, chemoprevention, both, or neither?. <i>European Heart Journal</i> , 2013 , 34, 3403-11	9.5	54
189	ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). <i>European Heart Journal</i> , 2013 , 34, 3035-87	9.5	1444
188	Platelet activation and inhibition in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2013 , 121, 1701-11	2.2	61
187	The recovery of platelet cyclooxygenase activity explains interindividual variability in responsiveness to low-dose aspirin in patients with and without diabetes. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 1220-30	15.4	171
186	Oxidative stress and platelet activation in subjects with moderate hyperhomocysteinaemia due to MTHFR 677 C→T polymorphism. <i>Thrombosis and Haemostasis</i> , 2012 , 108, 533-42	7	17
185	Aspirin and Other COX-1 inhibitors. <i>Handbook of Experimental Pharmacology</i> , 2012 , 137-64	3.2	19
184	The role of aspirin in cancer prevention. <i>Nature Reviews Clinical Oncology</i> , 2012 , 9, 259-67	19.4	352
183	Prostanoids, Aspirin, and Related Compounds 2012 , 168-171		
182	Aspirin-insensitive thromboxane biosynthesis in essential thrombocythemia is explained by accelerated renewal of the drug target. <i>Blood</i> , 2012 , 119, 3595-603	2.2	151
181	Cigarette smoking knowledge and perceptions among students in four Italian medical schools. <i>Nicotine and Tobacco Research</i> , 2012 , 14, 1065-72	4.9	29
180	Antiplatelet agents for the treatment and prevention of atherothrombosis. <i>European Heart Journal</i> , 2011 , 32, 2922-32	9.5	160
179	Prostaglandin E2 differentially modulates human platelet function through the prostanoid EP2 and EP3 receptors. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2011 , 336, 391-402	4.7	41
178	Non-steroidal anti-inflammatory drugs 2011 , 485-493		2
177	The future of antiplatelet therapy in cardiovascular disease. <i>Annual Review of Medicine</i> , 2010 , 61, 49-61	17.4	18
176	Nutraceuticals in diabetes and metabolic syndrome. <i>Cardiovascular Therapeutics</i> , 2010 , 28, 216-26	3.3	106
175	The contribution of cyclooxygenase-1 and -2 to persistent thromboxane biosynthesis in aspirin-treated essential thrombocythemia: implications for antiplatelet therapy. <i>Blood</i> , 2010 , 115, 1054-61	2.2	83

174	Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 828-37	15.4	62
173	Thromboxane and prostacyclin biosynthesis in heart failure of ischemic origin: effects of disease severity and aspirin treatment. <i>Journal of Thrombosis and Haemostasis</i> , 2010 , 8, 914-22	15.4	15
172	Platelet cyclooxygenase inhibition by low-dose aspirin is not reflected consistently by platelet function assays: implications for aspirin "resistance". <i>Journal of the American College of Cardiology</i> , 2009 , 53, 667-77	15.1	193
171	Nonsteroidal antiinflammatory drugs: past, present and future. <i>Pharmacological Research</i> , 2009 , 59, 285-92	15.2	60
170	Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. <i>Lancet, The</i> , 2009 , 373, 1849-60	40	2427
169	Low-dose aspirin, coxibs, and other NSAIDs: a clinical mosaic emerges. <i>Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics</i> , 2009 , 9, 31-9		51
168	Selective COX-2 inhibitors: where do we go from here?. <i>Lancet, The</i> , 2008 , 372, 1712-3	40	9
167	Aspirin: promise and resistance in the new millennium. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2008 , 28, s25-32	9.4	72
166	Antiplatelet drugs: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). <i>Chest</i> , 2008 , 133, 199S-233S	5.3	350
165	Guest authorship, mortality reporting, and integrity in rofecoxib studies. <i>JAMA - Journal of the American Medical Association</i> , 2008 , 300, 901; author reply 904-5	27.4	2
164	Authors' response to Drug Insight: aspirin resistance--fact or fashion?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007 , 4, E2-E2		
163	Drug insight: aspirin resistance--fact or fashion?. <i>Nature Clinical Practice Cardiovascular Medicine</i> , 2007 , 4, 42-50		94
162	Determinants of platelet activation in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2007 , 28, 336-42	5.6	62
161	Platelet activation and atherothrombosis. <i>New England Journal of Medicine</i> , 2007 , 357, 2482-94	59.2	1573
160	Aspirin for the control of platelet activation and prevention of thrombosis in essential thrombocythemia and polycythemia vera: current insights and rationale for future studies. <i>Seminars in Thrombosis and Hemostasis</i> , 2006 , 32, 251-9	5.3	14
159	Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Meta-analysis of randomised trials. <i>BMJ, The</i> , 2006 , 332, 1302-8	5.9	1000
158	Thromboxane-dependent CD40 ligand release in type 2 diabetes mellitus. <i>Journal of the American College of Cardiology</i> , 2006 , 47, 391-7	15.1	91
157	Insulin resistance as a determinant of platelet activation in obese women. <i>Journal of the American College of Cardiology</i> , 2006 , 48, 2531-8	15.1	98

156	The PGH-synthase system and isozyme-selective inhibition. <i>Journal of Cardiovascular Pharmacology</i> , 2006 , 47 Suppl 1, S1-6	3.1	20
155	Antiplatelet drugs. <i>British Journal of Pharmacology</i> , 2006 , 147 Suppl 1, S241-51	8.6	76
154	Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease. <i>Clinical Pharmacology and Therapeutics</i> , 2006 , 80, 264-74	6.1	89
153	Low-dose aspirin for the prevention of atherothrombosis. <i>New England Journal of Medicine</i> , 2005 , 353, 2373-83	59.2	870
152	Isoprostane formation and inhibition in atherothrombosis. <i>Current Opinion in Pharmacology</i> , 2005 , 5, 198-203	5.1	63
151	Lipid peroxidation in diabetes mellitus. <i>Antioxidants and Redox Signaling</i> , 2005 , 7, 256-68	8.4	248
150	Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. <i>Blood</i> , 2005 , 105, 2664-70	2.2	332
149	Determinants of the interindividual variability in response to antiplatelet drugs. <i>Journal of Thrombosis and Haemostasis</i> , 2005 , 3, 1597-602	15.4	68
148	Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. <i>Journal of Clinical Oncology</i> , 2005 , 23, 2224-32	2.2	504
147	Helicobacter pylori infection causes persistent platelet activation in vivo through enhanced lipid peroxidation. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2005 , 25, 246-51	9.4	25
146	Prostanoid Generation in Platelet Function 2005 , 267-281		
145	Expert consensus document on the use of antiplatelet agents. The task force on the use of antiplatelet agents in patients with atherosclerotic cardiovascular disease of the European society of cardiology. <i>European Heart Journal</i> , 2004 , 25, 166-81	9.5	245
144	Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. <i>Circulation</i> , 2004 , 109, 1468-71	16.7	195
143	Cyclooxygenase-2 expression and inhibition in atherothrombosis. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2004 , 24, 246-55	9.4	115
142	Efficacy and safety of low-dose aspirin in polycythemia vera. <i>New England Journal of Medicine</i> , 2004 , 350, 114-24	59.2	744
141	Modulation of the expression and activity of cyclooxygenases in normal and accelerated erythropoiesis. <i>Experimental Hematology</i> , 2004 , 32, 925-34	3.1	10
140	Determinants of F2-isoprostane biosynthesis and inhibition in man. <i>Chemistry and Physics of Lipids</i> , 2004 , 128, 149-63	3.7	76
139	Determinants of platelet activation in human essential hypertension. <i>Hypertension</i> , 2004 , 43, 64-70	8.5	73

138	Documento de Consenso de Expertos sobre el uso de agentes antiplaquetarios. <i>Revista Espanola De Cardiologia</i> , 2004 , 57, 963-980	1.5	0
137	Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. <i>Chest</i> , 2004 , 126, 234S-264S	5.3	494
136	Selective cyclooxygenase 2 inhibitors, aspirin, and cardiovascular disease: a reappraisal. <i>Arthritis and Rheumatism</i> , 2003 , 48, 12-20		86
135	Lipid and protein oxidation contribute to a prothrombotic state in patients with type 2 diabetes mellitus. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 250-6	15.4	55
134	Aspirin resistance: definition, mechanisms and clinical read-outs. <i>Journal of Thrombosis and Haemostasis</i> , 2003 , 1, 1710-3	15.4	224
133	Enhanced lipid peroxidation and platelet activation in the early phase of type 1 diabetes mellitus: role of interleukin-6 and disease duration. <i>Circulation</i> , 2003 , 107, 3199-203	16.7	119
132	Cyclooxygenase-2 expression is induced during human megakaryopoiesis and characterizes newly formed platelets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2002 , 99, 7634-9	11.5	260
131	Platelet activation in obese women: role of inflammation and oxidant stress. <i>JAMA - Journal of the American Medical Association</i> , 2002 , 288, 2008-14	27.4	406
130	Cyclooxygenase-2 polymorphism: putting a brake on the inflammatory response to vascular injury?. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2002 , 22, 1516-8	9.4	28
129	Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. <i>Journal of the National Cancer Institute</i> , 2002 , 94, 252-66	9.7	1182
128	Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. <i>Circulation</i> , 2002 , 106, 2800-5	16.7	180
127	Oxidative stress and platelet activation in homozygous homocystinuria. <i>Circulation</i> , 2001 , 104, 1124-8	16.7	103
126	The coxibs, selective inhibitors of cyclooxygenase-2. <i>New England Journal of Medicine</i> , 2001 , 345, 433-42	59.2	1214
125	Aspirin: new cardiovascular uses for an old drug. <i>American Journal of Medicine</i> , 2001 , 110, 62S-65S	2.4	52
124	Platelet-active drugs : the relationships among dose, effectiveness, and side effects. <i>Chest</i> , 2001 , 119, 39S-63S	5.3	380
123	Cyclooxygenase-selective inhibition of prostanoid formation: transducing biochemical selectivity into clinical read-outs. <i>Journal of Clinical Investigation</i> , 2001 , 108, 7-13	15.9	287
122	The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. <i>Clinical Pharmacology and Therapeutics</i> , 2001 , 70, 475-83	6.1	26
121	In vivo lipid peroxidation and platelet activation in cystic fibrosis. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2000 , 162, 1195-201	10.2	77

120	Effects of vitamin E supplementation on F(2)-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. <i>Circulation</i> , 2000 , 102, 539-45	16.7	94
119	Oxidant stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. <i>Circulation</i> , 2000 , 102, 1007-13	16.7	187
118	Innovation in COX-2 Technology. <i>Japanese Journal of Clinical Immunology</i> , 2000 , 23, 683-685		
117	Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. <i>Epidemiology</i> , 2000 , 11, 382-7	3.1	153
116	In vivo formation of 8-iso-prostaglandin f2alpha and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. <i>Circulation</i> , 1999 , 99, 224-9	16.7	646
115	Increased thromboxane biosynthesis is associated with poststroke dementia. <i>Stroke</i> , 1999 , 30, 1542-7	6.7	29
114	Increased platelet activation in the chronic phase after cerebral ischemia and intracerebral hemorrhage. <i>Stroke</i> , 1999 , 30, 546-9	6.7	46
113	Distinct roles of prostaglandin H synthases 1 and 2 in T-cell development. <i>Journal of Clinical Investigation</i> , 1999 , 103, 1469-77	15.9	106
112	Entry rate and metabolic handling of LTC4 in the human circulation 1999 , 139-146		
111	Effects of nimesulide on constitutive and inducible prostanoid biosynthesis in human beings. <i>Clinical Pharmacology and Therapeutics</i> , 1998 , 63, 672-81	6.1	40
110	Prevention of myocardial infarction and stroke by aspirin: different mechanisms? Different dosage?. <i>Thrombosis Research</i> , 1998 , 92, S7-12	8.2	27
109	Platelet-active drugs: the relationships among dose, effectiveness, and side effects. <i>Chest</i> , 1998 , 114, 470S-488S	5.3	139
108	Role of platelet activation in dementia. <i>Pathophysiology of Haemostasis and Thrombosis: International Journal on Haemostasis and Thrombosis Research</i> , 1998 , 28, 202-8		
107	Eicosanoids and Iso-Eicosanoids: Constitutive, Inducible and Transcellular Biosynthesis in Vascular Disease. <i>Thrombosis and Haemostasis</i> , 1998 , 79, 691-705	7	89
106	Unstable coronary artery disease: need for long-term antithrombotic treatment? Aspirin alone may not be the ideal antithrombotic strategy, but that's what we have adequate trial data for. <i>Cardiovascular Research</i> , 1997 , 33, 295-6	9.9	2
105	In vivo formation of 8-Epi-prostaglandin F2 alpha is increased in hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 3230-5	9.4	320
104	Isoprostanes: potential markers of oxidant stress in atherothrombotic disease. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1997 , 17, 2309-15	9.4	404
103	Platelet activation and inhibition in unstable coronary syndromes. <i>American Journal of Cardiology</i> , 1997 , 80, 17E-20E	3	38

102	Diabetes mellitus, hypercholesterolemia, and hypertension but not vascular disease per se are associated with persistent platelet activation in vivo. Evidence derived from the study of peripheral arterial disease. <i>Circulation</i> , 1997 , 96, 69-75	16.7	142
101	Differential suppression of thromboxane biosynthesis by indobufen and aspirin in patients with unstable angina. <i>Circulation</i> , 1997 , 96, 1109-16	16.7	107
100	Platelet activation and lipid peroxidation in patients with acute ischemic stroke. <i>Stroke</i> , 1997 , 28, 1557-63	6.7	67
99	Mechanisms of Bleeding and Thrombosis in Myeloproliferative Disorders. <i>Thrombosis and Haemostasis</i> , 1997 , 78, 617-621	7	49
98	Aspirin in polycythemia vera and essential thrombocythemia: current facts and perspectives. <i>Leukemia and Lymphoma</i> , 1996 , 22 Suppl 1, 83-6	1.9	10
97	Induction of prostaglandin endoperoxide synthase-2 in human monocytes associated with cyclo-oxygenase-dependent F2-isoprostane formation. <i>British Journal of Pharmacology</i> , 1996 , 118, 1285-93	8.6	62
96	Aspirin in ischemic cerebrovascular disease. How strong is the case for a different dosing regimen?. <i>Stroke</i> , 1996 , 27, 756-60	6.7	50
95	Growth abnormalities in cultured mesangial cells from rats with spontaneous glomerulosclerosis. <i>Kidney International</i> , 1995 , 47, 106-13	9.9	6
94	Long-term thromboxane-synthase inhibition prolongs survival in murine lupus nephritis. <i>Kidney International</i> , 1995 , 47, 1168-75	9.9	22
93	Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 1995 , 15, 247-51	9.4	205
92	Aspirin and other platelet-active drugs. The relationship among dose, effectiveness, and side effects. <i>Chest</i> , 1995 , 108, 247S-257S	5.3	73
91	Effects of the novel anti-inflammatory compounds, N-[2-(cyclohexyloxy)-4-nitrophenyl]methanesulphonamide (NS-398) and 5-methanesulphonamido-6-(2,4-difluorothio-phenyl)-1-indanone (L-745,337), on the cyclo-oxygenase activity of human blood prostaglandin endoperoxide synthase. <i>British Journal of Pharmacology</i> , 1995 , 114, 2122-31	8.6	66
90	Effects of nabumetone on prostanoid biosynthesis in humans. <i>Clinical Pharmacology and Therapeutics</i> , 1995 , 58, 335-41	6.1	31
89	Bleeding and thrombosis in myeloproliferative disorders: mechanisms and treatment. <i>Critical Reviews in Oncology/Hematology</i> , 1995 , 20, 203-22	7	62
88	Characterization of Biochemical and Functional Effects of Antiplatelet Drugs as a Key to Their Clinical Development. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 396-400	7	3
87	Increased Thromboxane Biosynthesis in Essential Thrombocythemia. <i>Thrombosis and Haemostasis</i> , 1995 , 74, 1225-1230	7	72
86	Aspirin as an antiplatelet drug. <i>New England Journal of Medicine</i> , 1994 , 330, 1287-94	59.2	774
85	Regulation of endothelin-1 biosynthesis. <i>Annals of the New York Academy of Sciences</i> , 1994 , 714, 109-21	6.5	19

84	Eicosanoid biosynthesis and metabolism in myeloproliferative disorders. <i>Annals of the New York Academy of Sciences</i> , 1994 , 744, 229-36	6.5	2
83	Evidence for episodic platelet activation in acute ischemic stroke. <i>Stroke</i> , 1994 , 25, 278-81	6.7	70
82	Effects of Unfractionated and Low Molecular Weight Heparins on Platelet Thromboxane Biosynthesis <i>In Vivo</i> <i>Thrombosis and Haemostasis</i> , 1994 , 72, 942-946	7	21
81	Differential effects of leukotriene C4 on endothelin-1 and prostacyclin release by cultured vascular cells. <i>Pharmacological Research</i> , 1993 , 27, 281-5	10.2	11
80	Aspirin, but not heparin, suppresses the transient increase in thromboxane biosynthesis associated with cardiac catheterization or coronary angioplasty. <i>Journal of the American College of Cardiology</i> , 1993 , 21, 1377-81	15.1	23
79	Pharmacologic modulation of the autonomic nervous system in the prevention of sudden cardiac death. A study with propranolol, methacholine and oxotremorine in conscious dogs with a healed myocardial infarction. <i>Journal of the American College of Cardiology</i> , 1993 , 22, 283-90	15.1	71
78	Enzyme immunometric assay for endothelin using tandem monoclonal antibodies. <i>Journal of Immunological Methods</i> , 1993 , 162, 179-92	2.5	27
77	In vivo expression of mutant preproendothelins: hierarchy of processing events but no strict requirement of Trp-Val at the processing site. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1993 , 90, 3923-7	11.5	13
76	Inhibition of thromboxane biosynthesis and platelet function by indobufen in type II diabetes mellitus. <i>Arteriosclerosis and Thrombosis: A Journal of Vascular Biology</i> , 1993 , 13, 1346-9		17
75	Increased thromboxane biosynthesis in patients with acute cerebral ischemia. <i>Stroke</i> , 1993 , 24, 219-23	6.7	80
74	Antiplatelet agents in the prevention of diabetic vascular complications. <i>Diabetes/metabolism Reviews</i> , 1993 , 9, 177-88		15
73	Abnormally high thromboxane biosynthesis in homozygous homocystinuria. Evidence for platelet involvement and probucol-sensitive mechanism. <i>Journal of Clinical Investigation</i> , 1993 , 92, 1400-6	15.9	108
72	Increased thromboxane biosynthesis in type IIa hypercholesterolemia. <i>Circulation</i> , 1992 , 85, 1792-8	16.7	158
71	Release of contracting autacoids by aortae of normal and atherosclerotic rabbits. <i>Journal of Cardiovascular Pharmacology</i> , 1992 , 20 Suppl 12, S208-10	3.1	14
70	Evidence for a direct vasoconstrictor effect of big endothelin-1 in the rat kidney. <i>European Journal of Pharmacology</i> , 1992 , 221, 267-73	5.3	9
69	Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. <i>Trends in Cardiovascular Medicine</i> , 1992 , 2, 15-20	6.9	25
68	Thromboxane biosynthesis and metabolism in relation to cardiovascular risk factors. <i>Agents and Actions Supplements</i> , 1992 , 37, 10-7	0.2	3
67	Proarrhythmic activity of intracoronary endothelin in dogs: relation to the site of administration and to changes in regional flow. <i>Journal of Cardiovascular Pharmacology</i> , 1991 , 17, 1007-14	3.1	39

66	In vivo platelet activation in diabetes mellitus. <i>Seminars in Thrombosis and Hemostasis</i> , 1991 , 17, 422-5	5.3	32
65	Heterologous in vivo processing of human preproendothelin 1 into bioactive peptides. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1991 , 88, 8939-43	11.5	7
64	Radioimmunoassay of 11-dehydrothromboxane B2. <i>Methods in Enzymology</i> , 1990 , 187, 34-42	1.7	3
63	Role of enhanced glomerular synthesis of thromboxane A2 in progressive kidney disease. <i>Kidney International</i> , 1990 , 38, 447-58	9.9	20
62	Long-term maintenance of thromboxane inhibition by two different aspirin regimens in patients with unstable angina. <i>Thrombosis Research</i> , 1990 , 60, 169-75	8.2	4
61	Thromboxane synthesis inhibitors and receptor antagonists. <i>Thrombosis Research</i> , 1990 , 11, 15-23	8.2	11
60	Thromboxane biosynthesis and platelet function in type II diabetes mellitus. <i>New England Journal of Medicine</i> , 1990 , 322, 1769-74	59.2	487
59	Effects of racemic, S- and R-indobufen on cyclooxygenase and lipoxygenase activities in human whole blood. <i>European Journal of Pharmacology</i> , 1990 , 191, 83-8	5.3	26
58	Dissociation of Platelet Activation and Spontaneous Myocardial Ischemia in Unstable Angina. <i>Thrombosis and Haemostasis</i> , 1990 , 63, 163-168	7	85
57	Eicosanoid biosynthesis and action: novel opportunities for pharmacological intervention. <i>FASEB Journal</i> , 1989 , 3, 1941-8	0.9	38
56	Improvement of renal function with selective thromboxane antagonism in lupus nephritis. <i>New England Journal of Medicine</i> , 1989 , 320, 421-5	59.2	100
55	Thromboxane biosynthesis and pharmacologic modulation in progressive glomerulosclerosis. <i>American Journal of Nephrology</i> , 1989 , 9 Suppl 1, 13-6	4.6	2
54	Fractional conversion of thromboxane A2 and B2 to urinary 2,3-dinor-thromboxane B2 and 11-dehydrothromboxane B2 in the cynomolgus monkey. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1989 , 992, 71-7	4	15
53	Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 1989 , 992, 66-70	4	83
52	Aspirin and human platelets: from clinical trials to acetylation of cyclooxygenase and back. <i>Trends in Pharmacological Sciences</i> , 1989 , 10, 453-8	13.2	103
51	Hemodynamic and tubular effects of endothelin and thromboxane in the isolated perfused rat kidney. <i>European Journal of Pharmacology</i> , 1989 , 171, 127-34	5.3	23
50	Renal prostaglandins: biochemistry and functional significance in man. <i>Contributions To Nephrology</i> , 1989 , 69, 55-66	1.6	
49	Platelet activation in unstable angina 1989 , 70-77		

48	Renal and Platelet Eicosanoids in Chronic Glomerular Disease 1989 , 121-136		
47	Plättchenaktivierung bei instabiler Angina pectoris 1989 , 76-84		
46	Platelet activating factor (PAF) as a mediator of injury in nephrotoxic nephritis. <i>Kidney International</i> , 1987 , 31, 1248-56	9.9	43
45	The clinical significance of inhibition of renal prostaglandin synthesis. <i>Kidney International</i> , 1987 , 32, 1-12	9.9	215
44	Effects of sulindac on renal and extrarenal eicosanoid synthesis. <i>Clinical Pharmacology and Therapeutics</i> , 1987 , 41, 380-3	6.1	29
43	Inhibition of renal prostaglandin synthesis in man: methodological and clinical implications. <i>Scandinavian Journal of Rheumatology</i> , 1986 , 62, 14-25	1.9	4
42	Aspirin for the prevention of coronary thrombosis: current facts and perspectives. <i>European Heart Journal</i> , 1986 , 7, 454-9	9.5	23
41	Long-lived enzymatic metabolites of thromboxane B2 in the human circulation. <i>Analytical Biochemistry</i> , 1986 , 155, 198-205	3.1	96
40	Renal effects of nonsteroidal anti-inflammatory drugs in chronic glomerular disease. <i>American Journal of Medicine</i> , 1986 , 81, 71-83	2.4	34
39	Estimated rate of thromboxane secretion into the circulation of normal humans. <i>Journal of Clinical Investigation</i> , 1986 , 77, 590-4	15.9	180
38	Low-dose aspirin in patients recovering from myocardial infarction. Evidence for a selective inhibition of thromboxane-related platelet function. <i>European Heart Journal</i> , 1985 , 6, 409-17	9.5	36
37	Clinical pharmacology of platelet cyclooxygenase inhibition. <i>Circulation</i> , 1985 , 72, 1177-84	16.7	362
36	Coronary flow regulation in patients with ischemic heart disease: release of purines and prostacyclin and the effect of inhibitors of prostaglandin formation. <i>Circulation</i> , 1985 , 71, 1113-20	16.7	72
35	Occurrence of Leukotrienes in Rat Brain 1985 , 17-26		
34	Physiologic variables affecting thromboxane B2 production in human whole blood. <i>Thrombosis Research</i> , 1985 , 37, 1-8	8.2	38
33	Selective inhibition of thromboxane-related platelet function by low-dose aspirin in patients after myocardial infarction. <i>American Journal of Cardiology</i> , 1985 , 55, 589-90	3	27
32	Functional significance of renal prostacyclin and thromboxane A2 production in patients with systemic lupus erythematosus. <i>Journal of Clinical Investigation</i> , 1985 , 76, 1011-8	15.9	156
31	The Effects of Low-Dose Aspirin and Selective Inhibitors of Thromboxane-Synthase on Eicosanoid Production in Man 1985 , 131-140		

30	Effects of sulindac and ibuprofen in patients with chronic glomerular disease. Evidence for the dependence of renal function on prostacyclin. <i>New England Journal of Medicine</i> , 1984 , 310, 279-83	59.2	312
29	Leukotriene C4 stimulates LH secretion from rat pituitary cells in vitro. <i>European Journal of Pharmacology</i> , 1984 , 106, 459-60	5.3	14
28	Tissue-selective inhibition of prostaglandin and thromboxane synthesis in man: investigative and therapeutic implications. <i>Clinical Physiology</i> , 1984 , 4, 443-7		3
27	Leukotrienes in the rat central nervous system. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1984 , 81, 6212-6	11.5	138
26	Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. <i>Circulation</i> , 1983 , 67, 1174-7	16.7	420
25	Release of two vasodilators, adenosine and prostacyclin, from isolated rabbit hearts during controlled hypoxia. <i>Journal of Physiology</i> , 1983 , 340, 487-501	3.9	60
24	Reduced platelet thromboxane formation in uremia. Evidence for a functional cyclooxygenase defect. <i>Journal of Clinical Investigation</i> , 1983 , 71, 762-8	15.9	120
23	Effect of prostaglandin synthesis inhibitors on basal and carbon dioxide stimulated cerebral blood flow in man. <i>Acta Physiologica Scandinavica</i> , 1983 , 117, 203-11		65
22	Effects of intravenous prostacyclin in variant angina. <i>Circulation</i> , 1982 , 65, 470-7	16.7	103
21	Cardiac formation of prostacyclin during cardioplegia in man. <i>Prostaglandins</i> , 1982 , 24, 5-19		14
20	Release of leukotriene C4 from human polymorphonuclear leucocytes as determined by radioimmunoassay. <i>FEBS Letters</i> , 1982 , 146, 111-4	3.8	100
19	Pharmacologic modulation of arachidonic acid metabolism in man. A minireview with emphasis on radioimmunological methods used to quantitate drug effects. <i>International Journal of Immunopharmacology</i> , 1982 , 4, 127-33		5
18	Evidence for a direct stimulatory effect of prostacyclin on renin release in man. <i>Journal of Clinical Investigation</i> , 1982 , 69, 231-9	15.9	176
17	Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. <i>Journal of Clinical Investigation</i> , 1982 , 69, 1366-72	15.9	723
16	Pulmonary formation of prostacyclin in man. <i>Prostaglandins</i> , 1981 , 22, 323-32		27
15	Prostacyclin stimulates the adenylate cyclase system of human thyroid tissue. <i>Prostaglandins</i> , 1981 , 22, 105-15		12
14	Prostacyclin does not affect insulin secretion in humans. <i>Prostaglandins</i> , 1981 , 21, 379-85		16
13	The synovial prostaglandin system in chronic inflammatory arthritis: differential effects of steroidal and nonsteroidal anti-inflammatory drugs. <i>British Journal of Pharmacology</i> , 1981 , 73, 893-901	8.6	104

12	Plasma and synovial fluid pharmacokinetics and prostaglandin inhibitory effect of indoprofen in patients with rheumatoid arthritis. <i>Scandinavian Journal of Rheumatology</i> , 1980 , 9, 123-6	1.9	13
11	Low dose aspirin and inhibition of thromboxane B2 production in healthy subjects. <i>Thrombosis Research</i> , 1980 , 17, 317-27	8.2	573
10	The involvement of arachidonic acid metabolism in the control of renin release. <i>Journal of Endocrinological Investigation</i> , 1980 , 3, 193-201	5.2	14
9	Characterization of furosemide-induced activation of the renal prostaglandin system. <i>European Journal of Pharmacology</i> , 1979 , 60, 181-7	5.3	68
8	Radioimmunoassay measurement of prostaglandins E2 and F2alpha in human urine. <i>Journal of Endocrinological Investigation</i> , 1979 , 2, 173-82	5.2	95
7	Evidence for an extra-renal origin of urinary prostaglandin E2 in healthy men. <i>Prostaglandins</i> , 1979 , 18, 623-9		76
6	Aspirin intolerance: unaltered susceptibility of platelet cyclo-oxygenase to inhibition by aspirin in vitro. <i>Journal of Allergy and Clinical Immunology</i> , 1978 , 62, 271-5	11.5	19
5	Release of prostaglandin F1alpha and F2alpha from superfused platelets: quantitative evaluation of the inhibitory effects of some aspirin-like drugs. <i>Prostaglandins</i> , 1975 , 9, 557-68		21
4	Echinococcus granulosus: evaluation of purified antigens immunoreactivity. <i>Experimental Parasitology</i> , 1974 , 35, 52-60	2.1	14
3	Letter: Do pituitary prostaglandins play an essential role in the action of LH-RH in man?. <i>Prostaglandins</i> , 1974 , 6, 345-8		5
2	Role of prostaglandin F2 in human cerebral vasospasm. <i>Journal of Neurosurgery</i> , 1974 , 41, 293-9	3.2	68
1	Behavior of pancreatic glucagon, insulin, and HGH in liver cirrhosis, after arginine and I.V. glucose. <i>Acta Diabetologica Latina</i> , 1974 , 11, 330-9		18